GLP-1 Receptor Agonist Market To Reach $201.79 Billion By 2033

December 2025 | Report Format: Electronic (PDF)

GLP-1 Receptor Agonist Market Growth & Trends

The global GLP-1 receptor agonist market size is expected to reach USD 201.79 billion by 2033, expanding at a CAGR of 12.78% from 2026 to 2033, according to a new report by Grand View Research, Inc. The strong product pipeline and formulation advancements are driving the market. In addition, novel innovative products are booming the market. In September 2019, Rybelsus, the first and only oral GLP-1 analog was approved by the U.S.FDA for improving the glycemic control in type-2 diabetes patients. It is a semaglutide-based product developed by Novo Nordisk, which is currently under review by European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA). After receiving the approval, the market may witness significant growth over the forecast period.

Furthermore, pharmaceutical companies are focusing on research collaborations for developing new GLP-1 products. For instance, in September 2018, Eli Lilly and Company entered into a license agreement with Chugai Pharmaceutical Co., Ltd for OWL833. OWL833 is Chugai’s proprietary oral GLP-1 agonist candidate and as per the agreement Eli Lilly will obtain global commercialization and development rights.

The companies are currently aiming on geographical expansion for increasing the sales output. Novo Nordisk is expanding its business by investing in the manufacturing unit located in North Carolina. The company holds around 50.0% of the market share of GLP-1 receptor agonists and is expected to dominate the market over the forecast period. Furthermore, in July 2018, Sanofi invested about USD 74.1 million in China for establishing an R&D hub to enhance its global reach.

The companies are also focusing on getting approval for other indications like obesity and major adverse cardiovascular events by authorities like the U.S.FDA, EMEA, and others for the existing products to increase their life cycle. For instance, in January 2020, Novo Nordisk received the U.S. FDA approval for Ozempic for Major Adverse Cardiovascular Events (MACE) in type 2 diabetes patients.

Request a free sample copy or view report summary: GLP-1 Receptor Agonist Market Report

GLP-1 Receptor Agonist Market Report Highlights

The ozempic segment dominated the market and accounted for a share of 37.77% in 2025. Ozempic is a brand-name U.S. FDA-approved prescription drug used to treat adults with type 2 diabetes.
The type 2 diabetes mellitus segment dominated the GLP-1 receptor agonist industry, with an 80.28% share in 2025, and is expected to grow at a significant CAGR over the forecast period. This can be attributed to the increased prevalence of type 2 diabetes mellitus and the wide availability of GLP-1 receptor agonists for its treatment.
The parenteral segment led the GLP-1 receptor agonist industry, accounting for the largest share of 92.58% in 2025, and is expected to grow at the fastest CAGR from 2026 to 2033. This dominance can be attributed to the wide availability of GLP-1 agonists for treating patients with diabetes and their high advantages over other drug administrations, such as high efficacy.
Retail pharmacies dominated the GLP-1 receptor agonist market, accounting for a 54.72% share in 2025, as they serve as the primary point of access for patients seeking chronic metabolic therapies. The wide geographic presence of retail chains supports the consistent availability of GLP-1 products, which helps meet the rising demand among patients with diabetes and obesity.
North America GLP-1 receptor agonist market accounted for a 77.72% share in 2024. Established brands including liraglutide (Victoza), dulaglutide (Trulicity), exenatide (Byetta/Bydureon), and semaglutide (Ozempic) dominate the GLP-1 receptor agonist market in North America.

GLP-1 Receptor Agonist Market Segmentation

Grand View Research has segmented the global GLP-1 receptor agonist market report based on product, application, route of administration, distribution channel, and region:

GLP-1 Receptor Agonist Product Outlook (Revenue, USD Million, 2021 - 2033)